Zobrazeno 1 - 10
of 32
pro vyhledávání: '"Fareeda Y. Coxon"'
Autor:
Naureen Starling, Sheela Rao, Elli Bourmpaki, Bijal Patel, Thomas K. Waddell, Catherine Cafferkey, Caroline Fong, David Cunningham, Michael Davidson, Ian Chau, David Watkins, Gayathri Anandappa, Charlotte Rees, Fareeda Y. Coxon, Clare Peckitt, Carys Morgan, Tom Roques, Jonathan Wadsley, Katharina von Loga, Ruwaida Begum
Publikováno v:
Journal of Clinical Oncology. 39:4015-4015
4015 Background: PLATFORM is a prospective, open-label, multicentre, adaptive phase II trial assessing maintenance therapy in patients (pts) with OG adenocarcinoma after platinum-based first-line induction chemotherapy. HER2 negative pts were initial
Autor:
Beate Haugk, Laura F. Ogle, Helen L. Reeves, Gary S. Beale, Richard Charnley, Dina Tiniakos, Sari F. Alhasan, Despina Televantou, Alastair D. Burt, David R. Newell, Anna Long, Fareeda Y. Coxon
Publikováno v:
British Journal of Cancer
Background: Pancreatic ductal adenocarcinoma (PDAC) is the fifth most common cause of cancer death in the UK. Its poor prognosis is attributed to late detection and limited therapeutic options. Expression of SULF2, an endosulfatase that modulates hep
Autor:
Russell D. Petty, Ruwaida Begum, Bijal Patel, Madeleine Hewish, Jonathan Wadsley, Katharina von Loga, Andrea Turner, Ian Chau, Michael Davidson, Catherine Cafferkey, David Cunningham, Fareeda Y. Coxon, Caroline Fong, Thomas K. Waddell, Gayathri Anandappa, Naureen Starling, Marlon Rebelatto, Carys Morgan, Tom Roques, Clare Peckitt
Publikováno v:
Journal of Clinical Oncology. 38:282-282
282 Background: Advanced OGA patients (pts) are treated with platinum-based 1st line chemotherapy but the role of maintenance therapy once disease control is obtained is unknown. Methods: PLATFORM is a prospective, open-label, adaptive phase II trial
Autor:
Anthony Evans, Tamas Hickish, William Greenhalf, David Cunningham, John P. Neoptolemos, Daniel H. Palmer, Charlotte L. Rawcliffe, Nick Wadd, Jonathan Wadsley, Paula Ghaneh, Fiona Campbell, Eithne Costello, Victoria Shaw, Stephen Falk, Fareeda Y. Coxon, Harpreet Wasan, Gary Middleton, Richard J. Jackson, Paul Ross, Juan W. Valle
Publikováno v:
Pancreatology. 18:S127-S128
Autor:
Heike I. Grabsch, David Cunningham, Nicholas P. West, Ruth E Langley, William H. Allum, Joyce Thompson, Avani Athauda, Naureen Starling, Erica Beaumont, Susan Pritchard, Fareeda Y. Coxon, Matthew Nankivell, Stephen Falk, Adrian Crellin, Suzanne Darby, Wasat Mansoor, Rupert Langer, D Alderson, Sebastian Cummins, Ian Chau
Publikováno v:
Journal of Clinical Oncology. 37:4022-4022
4022 Background: No large scale randomised data exists evaluating the impact of age and sex in patients (pts) undergoing potentially curative surgery and CTx for OG cancer. However, differences in age and sex may be contributing factors to variabilit
Autor:
Marc Peeters, H Kato, E Nagano, Fareeda Y. Coxon, Martyn Caplin, Daniel H. Palmer, Tim Meyer, Ivan Borbath, Justin Waters, Michael Larvin, Juan W. Valle
Publikováno v:
European Journal of Cancer. 46:526-533
To evaluate the combination of the gastrin antagonist Z-360 and gemcitabine for advanced pancreatic cancer.Previously untreated patients with PC were randomly allocated to Z-360 120 mg, 240 mg or placebo. Z-360/placebo was given on day -3 and gemcita
Autor:
Rupert Langer, Alicia Okines, D Alderson, Stephen Falk, Fareeda Y. Coxon, Adrian Crellin, Matthew Nankivell, S. P. Stenning, Jane M Blazeby, M Griffin, Ruth E Langley, C. Goldstein, Heike I. Grabsch, Richard Krysztopik, David Cunningham, S. Pritchard, Jeremy Thompson
Publikováno v:
Cunningham, D.; Langley, R.; Nankivell, M.; Blazeby, J.; Griffin, M.; Crellin, A.; Grabsch, H.; Okines, A.; Goldstein, C.; Falk, S.; Thompson, J.; Krysztopik, R.; Coxon, F.; Pritchard, S.; Langer, R.; Stenning, S.; Alderson, D. (2015). LBA-03 Neoadjuvant chemotherapy for resectable oesophageal and junctional adenocarcinoma: results from the UK Medical Research Council randomised OEO5 trial (ISRCTN 01852072). Annals of oncology, 26(Suppl 4), iv117-iv117. Oxford University Press 10.1093/annonc/mdv262.03
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3466c2af278d51b4017b418d86101263
Autor:
Cowell W, Oscar Bertetto, Tim Maughan, George Fountzilas, Joseph McKendrick, Fareeda Y. Coxon, Chris Twelves, Eduardo Díaz-Rubio, Jim Cassidy, Dufour P, Patrick G. Johnston, Malzyner A, Arie Figer, Beham A, Patel Kk, Lesniewski-Kmak K, S. Jelic, Jean-Yves Douillard, Bustová I, Werner Scheithauer, Louis P. Garrison
Publikováno v:
British Journal of Cancer
Oral capecitabine (Xeloda®) is an effective drug with favourable safety in adjuvant and metastatic colorectal cancer. Oxaliplatin-based therapy is becoming standard for Dukes' C colon cancer in patients suitable for combination therapy, but is not y
Autor:
Robert E. Hawkins, David Cunningham, John Bridgewater, Robert E. Coleman, S Sreedharan, F Valone, Malcolm A.S. Moore, William P. Steward, Fareeda Y. Coxon, Joseph C. Carmichael, T M Cosgriff, C H Redfern, J. Cassidy, A Bhatnagar, G. Chong, D Northfelt, Peter Harper, Jeremy Jones
Publikováno v:
Annals of Oncology. 17:437-442
Background: The monoclonal antibody 3H1 mimics the external structure of the carcinoembryonic antigen (CEA). It therefore has the potential, via the anti-idiotypic network, to stimulate immune responses to CEA that may benefit colorectal cancer patie
Autor:
Alan Anthoney, Tamas Hickish, A. Robinson, David Propper, Marianne Nicolson, Dean J. Naisbitt, Tom Roques, Mark Harrison, Stephen Falk, Jonathan Wadsley, Juan W. Valle, Martin Eatock, Eithne Costello, John P. Neoptolemos, W.P. Steward, Victoria Shaw, Jeff Evans, Fareeda Y. Coxon, Paul Ross, William Greenhalf, Nick Wadd, David Cunningham, Karen McAdam, Angel Garcia-Alonso, Paul Silcocks, Timothy Iveson, Charlotte L. Rawcliffe, Gemma Nanson, Trevor Cox, Gary Middleton, Pippa Corrie, Srinivasan Madhusudan, Caroline Archer
Publikováno v:
The Lancet. Oncology. 15(8)
Summary Background We aimed to assess the efficacy and safety of sequential or simultaneous telomerase vaccination (GV1001) in combination with chemotherapy in patients with locally advanced or metastatic pancreatic cancer. Methods TeloVac was a thre